Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management David S. Perlin Leading Article 26 September 2014 Pages: 1573 - 1585
Clinical Use of Rivaroxaban: Pharmacokinetic and Pharmacodynamic Rationale for Dosing Regimens in Different Indications Toby TrujilloPaul P. Dobesh Review Article Open access 02 September 2014 Pages: 1587 - 1603
New Directions for Rabbit Antithymocyte Globulin (Thymoglobulin®) in Solid Organ Transplants, Stem Cell Transplants and Autoimmunity Mohamad MohtyAndrea BacigalupoYvon Lebranchu Review Article Open access 28 August 2014 Pages: 1605 - 1634
Turning a Molecule into a Medicine: the Development of Indacaterol as a Novel Once-Daily Bronchodilator Treatment for Patients with COPD Lorraine MurphyStephen RennardDavid Young Review Article 12 September 2014 Pages: 1635 - 1657
OnabotulinumtoxinA (Botox®): A Review of its Use in the Treatment of Urinary Incontinence in Patients with Multiple Sclerosis or Subcervical Spinal Cord Injury Mark Sanford Adis Drug Evaluation 25 July 2014 Pages: 1659 - 1672
Lanreotide Autogel®: A Review of its Use in the Treatment of Patients with Acromegaly Celeste B. BurnessSohita DhillonSusan J. Keam Adis Drug Evaluation 06 September 2014 Pages: 1673 - 1691
Omalizumab: A Review of Its Use in Patients with Chronic Spontaneous Urticaria Paul L. McCormack Adis Drug Evaluation 13 September 2014 Pages: 1693 - 1699
Idelalisib: First Global Approval Anthony Markham R&D Insight Report 04 September 2014 Pages: 1701 - 1707
Ataluren: First Global Approval Nicola J. Ryan R&D Insight Report 06 September 2014 Pages: 1709 - 1714
Comment on “Treat-to-Target in Spondyloarthritis: Implications for Clinical Trial Designs” Daniel WendlingClément Prati Letter to the Editor 16 September 2014 Pages: 1715 - 1716
Author's Reply to Wendling and Prati: “Treat-to-Target in Spondyloarthritis: Implications for Clinical Trial Designs” James Cheng-Chung Wei Letter to the Editor 16 September 2014 Pages: 1717 - 1718